OHSU Team Identifies Mutations That Suggest Sutent Better Than Gleevec In Some GIST Cases | GenomeWeb
Research at the Oregon Health and Science University in Portland may lead to a diagnostic that could help physicians unsatisfied with Gleevec’s performance against gastrointestinal stromal tumors to switch to Sutent.
 
“We wondered if the same [genes of response for Gleevec] would hold true for Sutent, and what we found is that it’s exactly opposite,” according to Michael Heinrich, who led the study. Heinrich previously studied mutations linked to Gleevec response in GIST.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.